Telix Pharmaceuticals (NASDAQ:TLX) CEO Christian Behrenbruch Acquires 34,500 Shares

Key Points

• Telix CEO Christian Behrenbruch bought 34,500 shares on April 28 at an average $14.48 and a further 33,435 shares on April 29 at $14.87, spending roughly $997k total and increasing his stake to 20,709,500 shares (a 0.17% ownership rise).
• Telix missed quarterly expectations, reporting EPS of ($0.01) vs. $0.05 expected and revenue of $206.7M vs. $421.5M expected, while the stock traded around $11.11 with a 52‑week range of $6.28–$18.49.
• Analysts are mixed but the consensus is a Moderate Buy with an average price target of $21.13.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) CEO Christian Behrenbruch purchased 34,500 shares of Telix Pharmaceuticals stock in a transaction that occurred on Tuesday, April 28th. The stock was purchased at an average cost of $14.48 per share, for a total transaction of $499,560.00. Following the completion of the purchase, the chief executive officer owned 20,709,500 shares of the company's stock, valued at $299,873,560. This trade represents a 0.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Christian Behrenbruch also recently made the following trade(s):

• On Wednesday, April 29th, Christian Behrenbruch purchased 33,435 shares of Telix Pharmaceuticals stock. The stock was purchased at an average cost of $14.87 per share, for a total transaction of $497,178.45.

Telix Pharmaceuticals Stock Up 0.6%

TLX stock traded up $0.07 during midday trading on Wednesday, hitting $11.11. The stock had a trading volume of 87,368 shares, compared to its average volume of 208,018. The business has a 50-day moving average of $9.10 and a two-hundred day moving average of $8.77. Telix Pharmaceuticals Limited has a 52-week low of $6.28 and a 52-week high of $18.49. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) last released its earnings results on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing analysts' consensus estimates of $0.05 by ($0.06). The firm had revenue of $206.72 million during the quarter, compared to analysts' expectations of $421.50 million. Equities analysts anticipate that Telix Pharmaceuticals Limited will post 0.09 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Rhumbline Advisers raised its stake in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company's stock worth $25,000 after buying an additional 1,392 shares during the period. XTX Topco Ltd bought a new position in shares of Telix Pharmaceuticals in the fourth quarter worth about $89,000. OLD Mission Capital LLC bought a new position in shares of Telix Pharmaceuticals in the fourth quarter worth about $111,000. Vident Advisory LLC bought a new position in shares of Telix Pharmaceuticals in the fourth quarter worth about $204,000. Finally, IHT Wealth Management LLC bought a new position in shares of Telix Pharmaceuticals in the second quarter worth about $213,000.

Analyst Ratings Changes

A number of research firms have recently commented on TLX. Weiss Ratings reissued a "sell (d)" rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. Wedbush reaffirmed an "outperform" rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Citigroup increased their price objective on Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a "buy" rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen raised Telix Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, April 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $21.13.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.